COMMUNIQUÉS West-GlobeNewswire

Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)
30/10/2026
90 mg dose of fexlamose administered daily via nebulizer did not demonstrate improvement on trough FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not [...]
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
30/10/2026
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, [...]
Polk County Mosquito Control Reduces Aedes aegypti by Up to 95% with Sterile Insect Farms™ Sterile Male Releases
30/10/2026
BUFORD, Ga., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Polk County Mosquito Control has reduced populations of Aedes aegypti (its top problem species and a primary carrier of dengue, Zika, and chikungunya) by up to 95% after [...]
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
30/10/2026
New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: [...]
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
30/10/2026
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases [...]
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
30/10/2026
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $ [...]
Sienna Completes Acquisition in Ottawa
30/10/2026
MARKHAM, Ontario, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed $170.7 million acquisition of [...]
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
30/10/2026
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological [...]
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
30/10/2026
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes [...]
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
30/10/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for [...]
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
30/10/2026
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A [...]
Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B
30/10/2026
Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP toxicology study establishes [...]
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
30/10/2026
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders [...]
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
30/10/2026
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosures KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC [...]
Femasys Appoints John Moorhead to Board of Directors
30/10/2026
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the [...]
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026
PRESS RELEASE, October 30, 2026 – 08:00 CDT Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026 ITASCA, IL, US – October 30, 2026. Today, Biocartis , an innovative [...]
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax [...]
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum